{"success":true,"data":{"pressRelease":{"id":"81145","rtpr_id":"nBw1wm1sRa","ticker":"MEDCL","exchange":"Euronext Paris","all_tickers":["MEDCL"],"title":"Medincell: Half-Year Liquidity Contract Statement","author":"Business Wire","published_at":"2026-07-06T16:40:00.133Z","article_body":"Medincell: Half-Year Liquidity Contract Statement\n\nRegulatory News:\n\nUnder the liquidity contract entrusted by Medincell (Paris:MEDCL) to\nRothschild Martin Maurel, the following resources were included in the\nliquidity account at June 30, 2026:\n\n\n * 676 shares\n\n * 1 173 521 €\n\nOver the period from 01/01/2026 to 30/06/2026, a total of:\n            Number of executions  Number of shares  Traded volume in EUR  \n Buy side   9,138                 592,263           14,869,875.91         \n Sell side  10,478                592,567           14,883,592.32         \n\n\nThe following resources were included in the liquidity account at December 31,\n2025:\n\n\n * 980 shares\n\n * 1 159 804 €\n\nFollowing the reorganization within the Rothschild & Co group and the\ntransfer of Rothschild & Co Martin Maurel’s market-making activities to\nRothschild & Co Global Markets Solutions (Europe) SA, the latter has\nassumed management of the liquidity contract for Medincell [Euronext Paris\nFR0004065605] effective July 1, 2026. This transfer has no impact on the terms\nof the liquidity contract or on the resources allocated to its implementation,\nwhich are disclosed in the semiannual reports.\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nThese treatments combine active pharmaceutical ingredients with our\nproprietary BEPO(®) / BEPO(®) Star technologies, which enables controlled\ndrug delivery at therapeutic levels for several days, weeks, or months\nfollowing a subcutaneous or local injection of a small, fully bioresorbable\ndepot.\n\nRisperidone LAI was the first treatment based on BEPO(®) technology to\nreceive FDA approval, initially for schizophrenia in April 2023, and\nsubsequently for Bipolar I Disorder in October 2025. It is marketed in the\nUnited States by Teva under the brand name UZEDY(®). Medincell’s\nrisperidone LAI was also approved for schizophrenia in Canada and South Korea\nin 2025.\n\nA New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment\nfor schizophrenia in adults was submitted to the U.S. FDA in December 2025 by\nMedincell’s partner, Teva. U.S. FDA accepted Teva’s New NDA for Olanzapine\nLAI on February 20, 2026. A European Marketing Authorization Application (MAA)\nwas also accepted by EMA in May 2026.\n\nMedincell’s investigational pipeline includes numerous innovative\ntherapeutic candidates in various stages of development, from formulation to\nPhase 3 clinical trials. We collaborate with leading pharmaceutical companies\nand foundations to advance global health through new treatment options.\n\nHeadquartered in Montpellier, France, Medincell employs over 140 people\nrepresenting more than 25 nationalities.\n\nmedincell.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medincell.com%2F&esheet=54565638&newsitemid=20260706818402&lan=en-US&anchor=medincell.com&index=1&md5=5d0ef20be0a7c9be41199a0ec0d57633)\n\nUZEDY(®) is a trademark of Teva Pharmaceuticals. Medincell’s BEPO(®)\ntechnology is licensed to Teva as SteadyTeq™, a trademark of Teva\nPharmaceuticals.\n\nThis press release contains forward-looking statements, including statements\nregarding Company’s expectations for (i) the timing, progress and outcome of\nits clinical trials; (ii) the clinical benefits and competitive positioning of\nits product candidates; (iii) its ability to obtain regulatory approvals,\ncommence commercial production and achieve market penetration and sales; (iv)\nits future product portfolio; (v) its future partnering arrangements; (vi) its\nfuture capital needs, capital expenditure plans and ability to obtain funding;\nand (vii) prospective financial matters regarding our business. Although the\nCompany believes that its expectations are based on reasonable assumptions,\nany statements other than statements of historical facts that may be contained\nin this press release relating to future events are forward-looking statements\nand subject to change without notice, factors beyond the Company's control and\nthe Company's financial capabilities.\n\nThese statements may include, but are not limited to, any statement beginning\nwith, followed by or including words or phrases such as \"objective\",\n\"believe\", \"anticipate\", “expect”, \"foresee\", \"aim\", \"intend\", \"may\",\n\"anticipate\", \"estimate\", \"plan\", \"project\", \"will\", \"may\", \"probably\",\n“potential”, \"should\", \"could\" and other words and phrases of the same\nmeaning or used in negative form. Forward-looking statements are subject to\ninherent risks and uncertainties beyond the Company's control that may, if\nany, cause actual results, performance, or achievements to differ materially\nfrom those anticipated or expressed explicitly or implicitly by such\nforward-looking statements. A list and description of these risks,\ncontingencies and uncertainties can be found in the documents filed by the\nCompany with the Autorité des Marchés Financiers (the \"AMF\") pursuant to its\nregulatory obligations, including the Company's universal registration\ndocument, filed with the AMF on July 29, 2025, under number D. 25-0580 (the\n\"Universal Registration Document\"), as well as in the documents and reports to\nbe published subsequently by the Company. In particular, readers' attention is\ndrawn to the section entitled \"Facteurs de Risques\" on page 30 et seq. 26 of\nthe Registration Document.\n\nAny forward-looking statements made by or on behalf of the Company speak only\nas of the date they are made. Except as required by law, the Company does not\nundertake any obligation to publicly update these forward-looking statements\nor to update the reasons why actual results could differ materially from those\nanticipated by the forward-looking statements, including in the event that new\ninformation becomes available. The Company's update of one or more\nforward-looking statements does not imply that the Company will make any\nfurther updates to such forward-looking statements or other forward-looking\nstatements. Readers are cautioned not to place undue reliance on these\nforward-looking statements.\n\nThis press release is for information purposes only. The information contained\nherein does not constitute an offer to sell or a solicitation of an offer to\nbuy or subscribe for the Company's shares in any jurisdiction, in particular\nin France. Similarly, this press release does not constitute investment advice\nand should not be treated as such. It is not related to the investment\nobjectives, financial situation, or specific needs of any recipient. It should\nnot deprive the recipients of the opportunity to exercise their own judgment.\nAll opinions expressed in this document are subject to change without notice.\nThe distribution of this press release may be subject to legal restrictions in\ncertain jurisdictions.\n\nAPPENDICES - Rothschild Martin Maurel from 01/01/2026 to 30/06/2026\n DATE        NB_ACHAT  NB_VENTE  QTE_ACHAT  QTE_VENTE  CAPITAUX_ACHETES  CAPITAUX_VENDUS  \n 02/01/2026  12        3         573        201        14 290,62         5 099,37         \n 05/01/2026  68        57        2 715      1 567      66 028,80         38 375,83        \n 06/01/2026  74        84        2 100      2 800      51 009,00         68 264,00        \n 07/01/2026  88        162       1 500      3 300      36 990,00         81 840,00        \n 08/01/2026  90        86        6 050      3 800      156 755,50        99 066,00        \n 09/01/2026  77        94        3 857      3 107      99 356,32         80 626,65        \n 12/01/2026  49        88        1 441      4 441      37 480,41         115 865,69       \n 13/01/2026  72        208       5 000      4 000      132 300,00        105 560,00       \n 14/01/2026  108       99        4 620      5 620      124 924,80        152 526,80       \n 15/01/2026  168       130       8 907      3 907      242 982,96        105 449,93       \n 16/01/2026  113       313       5 129      10 129     142 791,36        281 383,62       \n 19/01/2026  36        13        2 251      651        61 925,01         18 175,92        \n 20/01/2026  116       165       2 976      3 776      79 072,32         100 668,16       \n 21/01/2026  81        70        3 253      4 053      87 505,70         109 795,77       \n 22/01/2026  128       139       4 459      4 459      126 858,55        127 170,68       \n 23/01/2026  77        39        3 113      3 113      89 311,97         89 561,01        \n 26/01/2026  145       57        6 287      1 287      174 841,47        35 933,04        \n 27/01/2026  63        180       4 030      5 930      110 099,60        162 066,90       \n 28/01/2026  102       158       5 115      4 215      137 900,40        115 786,05       \n 29/01/2026  174       132       4 980      2 180      117 229,20        51 709,60        \n 30/01/2026  22        9         1 805      905        41 280,35         20 941,70        \n 01/2026     1 863     2 286     80 161     73 441     2 130 934,34      1 965 866,72     \n 02/02/2026  98        146       1 932      2 632      43 624,56         59 746,40        \n 03/02/2026  57        116       7 500      8 000      174 075,00        185 760,00       \n 04/02/2026  98        99        3 082      3 082      70 855,18         71 070,92        \n 05/02/2026  68        163       1 271      2 271      29 360,10         52 982,43        \n 06/02/2026  59        202       2 237      5 237      52 278,69         122 860,02       \n 09/02/2026  62        122       1 356      3 056      32 747,40         73 802,40        \n 10/02/2026  173       113       3 719      2 519      89 367,57         60 758,28        \n 11/02/2026  231       376       4 530      5 780      105 322,50        136 234,60       \n 12/02/2026  15        21        950        800        22 895,00         19 352,00        \n 13/02/2026  55        119       1 350      2 250      32 589,00         54 877,50        \n 16/02/2026  171       212       21 700     10 700     529 914,00        259 368,00       \n 17/02/2026  66        382       1 482      12 482     35 894,04         305 309,72       \n 18/02/2026  101       55        4 502      552        108 678,28        13 308,72        \n 19/02/2026  155       106       2 569      3 801      62 195,49         92 212,26        \n 20/02/2026  34        31        2 048      2 048      48 865,28         48 803,84        \n 23/02/2026  284       314       12 851     15 040     310 737,18        364 569,60       \n 24/02/2026  117       89        4 643      4 662      112 732,04        113 566,32       \n 25/02/2026  90        72        3 060      3 570      74 541,60         87 143,70        \n 26/02/2026  181       188       4 954      2 443      123 503,22        60 464,25        \n 27/02/2026  122       67        4 406      3 815      103 541,00        89 805,10        \n 02/2026     2 237     2 993     90 142     94 740     2 163 717,13      2 271 996,06     \n 02/03/2026  127       129       3 032      3 032      69 645,04         70 160,48        \n 03/03/2026  30        15        1 704      1 674      38 425,20         37 564,56        \n 04/03/2026  32        99        1 006      3 635      22 363,38         84 113,90        \n 05/03/2026  65        73        1 341      945        31 178,25         22 150,80        \n 06/03/2026  47        39        3 403      3 403      74 321,52         74 423,61        \n 09/03/2026  9         10        475        815        9 851,50          17 432,85        \n 10/03/2026  136       109       2 839      2 939      63 621,99         66 009,94        \n 11/03/2026  81        56        3 829      3 084      85 271,83         68 341,44        \n 12/03/2026  32        22        1 387      2 030      29 598,58         43 178,10        \n 13/03/2026  100       51        7 450      7 350      154 885,50        152 733,00       \n 16/03/2026  72        31        6 523      6 523      135 547,94        135 678,40       \n 17/03/2026  75        77        7 900      7 900      162 819,00        163 135,00       \n 18/03/2026  114       67        17 539     17 539     365 863,54        365 688,15       \n 19/03/2026  55        41        3 760      3 760      77 230,40         77 305,60        \n 20/03/2026  46        31        3 756      3 104      77 411,16         64 097,60        \n 23/03/2026  33        37        2 403      3 016      50 078,52         62 431,20        \n 24/03/2026  60        43        3 755      3 755      79 643,55         79 643,55        \n 25/03/2026  45        46        3 800      3 137      83 676,00         68 888,52        \n 26/03/2026  42        30        2 902      2 902      62 799,28         62 973,40        \n 27/03/2026  80        84        6 675      6 712      147 250,50        148 469,44       \n 30/03/2026  67        53        3 821      3 922      83 832,74         86 127,12        \n 31/03/2026  52        67        4 473      4 985      99 926,82         111 514,45       \n 03/2026     1 400     1 210     93 773     96 162     2 005 242,24      2 062 061,11     \n 01/04/2026  67        53        4 048      4 048      94 520,80         94 480,32        \n 02/04/2026  50        38        3 492      3 487      79 617,60         79 538,47        \n 07/04/2026  46        15        2 648      1 950      58 785,60         42 978,00        \n 08/04/2026  47        42        3 600      3 676      81 612,00         83 114,36        \n 09/04/2026  50        55        3 461      4 502      77 941,72         101 520,10       \n 10/04/2026  51        36        4 189      2 585      99 195,52         61 135,25        \n 13/04/2026  48        56        2 862      3 512      65 911,86         81 056,96        \n 14/04/2026  38        54        2 365      3 193      56 665,40         76 376,56        \n 15/04/2026  52        42        3 881      2 997      96 986,19         75 074,85        \n 16/04/2026  72        57        4 272      3 069      103 083,36        73 932,21        \n 17/04/2026  50        59        4 193      4 298      100 715,86        103 452,86       \n 20/04/2026  57        50        3 834      3 926      90 827,46         92 928,42        \n 21/04/2026  81        124       6 639      8 172      161 062,14        198 334,44       \n 22/04/2026  46        41        3 300      3 300      80 949,00         81 147,00        \n 23/04/2026  96        95        7 358      7 358      178 505,08        178 799,40       \n 24/04/2026  45        28        3 670      1 994      86 612,00         47 118,22        \n 27/04/2026  96        99        5 223      6 607      122 740,50        155 859,13       \n 28/04/2026  52        21        3 374      1 728      78 411,76         40 176,00        \n 29/04/2026  32        55        2 468      4 762      57 504,40         111 907,00       \n 30/04/2026  45        39        3 176      3 275      76 986,24         79 451,50        \n 04/2026     1 121     1 059     78 053     78 439     1 848 634,49      1 858 381,05     \n 04/05/2026  77        71        5 918      5 730      142 387,08        138 551,40       \n 05/05/2026  49        43        3 349      3 349      82 787,28         82 921,24        \n 06/05/2026  50        41        6 600      4 391      175 362,00        116 405,41       \n 07/05/2026  81        111       11 385     11 344     302 954,85        302 431,04       \n 08/05/2026  64        59        7 824      7 789      203 815,20        203 137,12       \n 11/05/2026  92        104       14 259     14 962     382 426,38        401 280,84       \n 12/05/2026  72        122       9 608      10 540     257 974,80        284 053,00       \n 13/05/2026  73        89        11 391     10 663     321 226,20        300 589,97       \n 14/05/2026  42        54        5 148      6 289      143 989,56        176 469,34       \n 15/05/2026  80        48        9 279      4 779      261 575,01        134 863,38       \n 18/05/2026  43        39        3 465      2 865      92 654,10         76 638,75        \n 19/05/2026  64        44        4 472      4 472      116 003,68        116 137,84       \n 20/05/2026  18        74        2 072      6 287      55 674,64         169 497,52       \n 21/05/2026  31        32        3 134      3 134      83 395,74         83 427,08        \n 22/05/2026  90        75        12 451     12 451     336 550,53        337 795,63       \n 25/05/2026  64        23        5 909      2 046      158 774,83        55 242,00        \n 26/05/2026  43        60        3 599      3 599      95 841,37         95 913,35        \n 27/05/2026  36        47        2 754      3 771      73 779,66         101 590,74       \n 28/05/2026  15        50        1 249      3 711      34 097,70         103 351,35       \n 29/05/2026  70        67        5 448      4 767      156 412,08        137 527,95       \n 05/2026     1 154     1 253     129 314    126 939    3 477 682,69      3 417 824,95     \n 01/06/2026  103       99        12 405     9 322      357 388,05        269 219,36       \n 02/06/2026  65        52        5 454      3 189      150 639,48        87 729,39        \n 03/06/2026  63        41        4 466      2 812      118 482,98        74 489,88        \n 04/06/2026  26        24        1 900      1 900      49 780,00         49 875,00        \n 05/06/2026  41        69        3 061      5 853      83 197,98         160 079,55       \n 08/06/2026  52        129       4 260      10 463     117 576,00        290 034,36       \n 09/06/2026  81        82        11 019     7 969      308 311,62        222 972,62       \n 10/06/2026  94        40        7 055      4 017      189 708,95        108 097,47       \n 11/06/2026  78        158       5 408      9 722      145 475,20        263 174,54       \n 12/06/2026  53        69        4 680      4 345      128 512,80        119 791,65       \n 15/06/2026  74        152       6 000      5 720      166 860,00        159 302,00       \n 16/06/2026  95        167       12 764     15 301     358 923,68        430 876,16       \n 17/06/2026  89        71        4 892      4 892      118 141,80        118 092,88       \n 18/06/2026  137       150       11 990     9 981      300 709,20        250 722,72       \n 19/06/2026  35        11        4 376      1 946      106 424,32        47 209,96        \n 22/06/2026  48        93        4 296      6 311      105 896,40        156 007,92       \n 23/06/2026  28        54        2 307      4 804      59 036,13         123 366,72       \n 24/06/2026  45        26        3 547      1 452      89 916,45         36 387,12        \n 25/06/2026  34        32        2 180      2 417      54 521,80         60 594,19        \n 26/06/2026  42        45        2 550      2 730      65 713,50         70 406,70        \n 29/06/2026  48        72        4 203      4 896      112 051,98        130 576,32       \n 30/06/2026  32        41        2 007      2 804      56 396,70         78 455,92        \n 06/2026     1 363     1 677     120 820    122 846    3 243 665,02      3 307 462,43     \n S1/2026     9 138     10 478    592 263    592 567    14 869 875,91     14 883 592,32    \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260706818402/en/\n(https://www.businesswire.com/news/home/20260706818402/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\nNicolas Mérigeau / Gaëlle Fromaigeat \n\nMedia Relations\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\nLouis-Victor Delouvrier / Alban Dufumier \n\nInvestor Relations France\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1wm1sRa","title":"Medincell: Half-Year Liquidity Contract Statement","author":"Business Wire","ticker":"MEDCL","created":"2026-07-06T16:40:00.133Z","tickers":["MEDCL"],"exchange":"Euronext Paris","article_body":"Medincell: Half-Year Liquidity Contract Statement\n\nRegulatory News:\n\nUnder the liquidity contract entrusted by Medincell (Paris:MEDCL) to\nRothschild Martin Maurel, the following resources were included in the\nliquidity account at June 30, 2026:\n\n\n * 676 shares\n\n * 1 173 521 €\n\nOver the period from 01/01/2026 to 30/06/2026, a total of:\n            Number of executions  Number of shares  Traded volume in EUR  \n Buy side   9,138                 592,263           14,869,875.91         \n Sell side  10,478                592,567           14,883,592.32         \n\n\nThe following resources were included in the liquidity account at December 31,\n2025:\n\n\n * 980 shares\n\n * 1 159 804 €\n\nFollowing the reorganization within the Rothschild & Co group and the\ntransfer of Rothschild & Co Martin Maurel’s market-making activities to\nRothschild & Co Global Markets Solutions (Europe) SA, the latter has\nassumed management of the liquidity contract for Medincell [Euronext Paris\nFR0004065605] effective July 1, 2026. This transfer has no impact on the terms\nof the liquidity contract or on the resources allocated to its implementation,\nwhich are disclosed in the semiannual reports.\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nThese treatments combine active pharmaceutical ingredients with our\nproprietary BEPO(®) / BEPO(®) Star technologies, which enables controlled\ndrug delivery at therapeutic levels for several days, weeks, or months\nfollowing a subcutaneous or local injection of a small, fully bioresorbable\ndepot.\n\nRisperidone LAI was the first treatment based on BEPO(®) technology to\nreceive FDA approval, initially for schizophrenia in April 2023, and\nsubsequently for Bipolar I Disorder in October 2025. It is marketed in the\nUnited States by Teva under the brand name UZEDY(®). Medincell’s\nrisperidone LAI was also approved for schizophrenia in Canada and South Korea\nin 2025.\n\nA New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment\nfor schizophrenia in adults was submitted to the U.S. FDA in December 2025 by\nMedincell’s partner, Teva. U.S. FDA accepted Teva’s New NDA for Olanzapine\nLAI on February 20, 2026. A European Marketing Authorization Application (MAA)\nwas also accepted by EMA in May 2026.\n\nMedincell’s investigational pipeline includes numerous innovative\ntherapeutic candidates in various stages of development, from formulation to\nPhase 3 clinical trials. We collaborate with leading pharmaceutical companies\nand foundations to advance global health through new treatment options.\n\nHeadquartered in Montpellier, France, Medincell employs over 140 people\nrepresenting more than 25 nationalities.\n\nmedincell.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medincell.com%2F&esheet=54565638&newsitemid=20260706818402&lan=en-US&anchor=medincell.com&index=1&md5=5d0ef20be0a7c9be41199a0ec0d57633)\n\nUZEDY(®) is a trademark of Teva Pharmaceuticals. Medincell’s BEPO(®)\ntechnology is licensed to Teva as SteadyTeq™, a trademark of Teva\nPharmaceuticals.\n\nThis press release contains forward-looking statements, including statements\nregarding Company’s expectations for (i) the timing, progress and outcome of\nits clinical trials; (ii) the clinical benefits and competitive positioning of\nits product candidates; (iii) its ability to obtain regulatory approvals,\ncommence commercial production and achieve market penetration and sales; (iv)\nits future product portfolio; (v) its future partnering arrangements; (vi) its\nfuture capital needs, capital expenditure plans and ability to obtain funding;\nand (vii) prospective financial matters regarding our business. Although the\nCompany believes that its expectations are based on reasonable assumptions,\nany statements other than statements of historical facts that may be contained\nin this press release relating to future events are forward-looking statements\nand subject to change without notice, factors beyond the Company's control and\nthe Company's financial capabilities.\n\nThese statements may include, but are not limited to, any statement beginning\nwith, followed by or including words or phrases such as \"objective\",\n\"believe\", \"anticipate\", “expect”, \"foresee\", \"aim\", \"intend\", \"may\",\n\"anticipate\", \"estimate\", \"plan\", \"project\", \"will\", \"may\", \"probably\",\n“potential”, \"should\", \"could\" and other words and phrases of the same\nmeaning or used in negative form. Forward-looking statements are subject to\ninherent risks and uncertainties beyond the Company's control that may, if\nany, cause actual results, performance, or achievements to differ materially\nfrom those anticipated or expressed explicitly or implicitly by such\nforward-looking statements. A list and description of these risks,\ncontingencies and uncertainties can be found in the documents filed by the\nCompany with the Autorité des Marchés Financiers (the \"AMF\") pursuant to its\nregulatory obligations, including the Company's universal registration\ndocument, filed with the AMF on July 29, 2025, under number D. 25-0580 (the\n\"Universal Registration Document\"), as well as in the documents and reports to\nbe published subsequently by the Company. In particular, readers' attention is\ndrawn to the section entitled \"Facteurs de Risques\" on page 30 et seq. 26 of\nthe Registration Document.\n\nAny forward-looking statements made by or on behalf of the Company speak only\nas of the date they are made. Except as required by law, the Company does not\nundertake any obligation to publicly update these forward-looking statements\nor to update the reasons why actual results could differ materially from those\nanticipated by the forward-looking statements, including in the event that new\ninformation becomes available. The Company's update of one or more\nforward-looking statements does not imply that the Company will make any\nfurther updates to such forward-looking statements or other forward-looking\nstatements. Readers are cautioned not to place undue reliance on these\nforward-looking statements.\n\nThis press release is for information purposes only. The information contained\nherein does not constitute an offer to sell or a solicitation of an offer to\nbuy or subscribe for the Company's shares in any jurisdiction, in particular\nin France. Similarly, this press release does not constitute investment advice\nand should not be treated as such. It is not related to the investment\nobjectives, financial situation, or specific needs of any recipient. It should\nnot deprive the recipients of the opportunity to exercise their own judgment.\nAll opinions expressed in this document are subject to change without notice.\nThe distribution of this press release may be subject to legal restrictions in\ncertain jurisdictions.\n\nAPPENDICES - Rothschild Martin Maurel from 01/01/2026 to 30/06/2026\n DATE        NB_ACHAT  NB_VENTE  QTE_ACHAT  QTE_VENTE  CAPITAUX_ACHETES  CAPITAUX_VENDUS  \n 02/01/2026  12        3         573        201        14 290,62         5 099,37         \n 05/01/2026  68        57        2 715      1 567      66 028,80         38 375,83        \n 06/01/2026  74        84        2 100      2 800      51 009,00         68 264,00        \n 07/01/2026  88        162       1 500      3 300      36 990,00         81 840,00        \n 08/01/2026  90        86        6 050      3 800      156 755,50        99 066,00        \n 09/01/2026  77        94        3 857      3 107      99 356,32         80 626,65        \n 12/01/2026  49        88        1 441      4 441      37 480,41         115 865,69       \n 13/01/2026  72        208       5 000      4 000      132 300,00        105 560,00       \n 14/01/2026  108       99        4 620      5 620      124 924,80        152 526,80       \n 15/01/2026  168       130       8 907      3 907      242 982,96        105 449,93       \n 16/01/2026  113       313       5 129      10 129     142 791,36        281 383,62       \n 19/01/2026  36        13        2 251      651        61 925,01         18 175,92        \n 20/01/2026  116       165       2 976      3 776      79 072,32         100 668,16       \n 21/01/2026  81        70        3 253      4 053      87 505,70         109 795,77       \n 22/01/2026  128       139       4 459      4 459      126 858,55        127 170,68       \n 23/01/2026  77        39        3 113      3 113      89 311,97         89 561,01        \n 26/01/2026  145       57        6 287      1 287      174 841,47        35 933,04        \n 27/01/2026  63        180       4 030      5 930      110 099,60        162 066,90       \n 28/01/2026  102       158       5 115      4 215      137 900,40        115 786,05       \n 29/01/2026  174       132       4 980      2 180      117 229,20        51 709,60        \n 30/01/2026  22        9         1 805      905        41 280,35         20 941,70        \n 01/2026     1 863     2 286     80 161     73 441     2 130 934,34      1 965 866,72     \n 02/02/2026  98        146       1 932      2 632      43 624,56         59 746,40        \n 03/02/2026  57        116       7 500      8 000      174 075,00        185 760,00       \n 04/02/2026  98        99        3 082      3 082      70 855,18         71 070,92        \n 05/02/2026  68        163       1 271      2 271      29 360,10         52 982,43        \n 06/02/2026  59        202       2 237      5 237      52 278,69         122 860,02       \n 09/02/2026  62        122       1 356      3 056      32 747,40         73 802,40        \n 10/02/2026  173       113       3 719      2 519      89 367,57         60 758,28        \n 11/02/2026  231       376       4 530      5 780      105 322,50        136 234,60       \n 12/02/2026  15        21        950        800        22 895,00         19 352,00        \n 13/02/2026  55        119       1 350      2 250      32 589,00         54 877,50        \n 16/02/2026  171       212       21 700     10 700     529 914,00        259 368,00       \n 17/02/2026  66        382       1 482      12 482     35 894,04         305 309,72       \n 18/02/2026  101       55        4 502      552        108 678,28        13 308,72        \n 19/02/2026  155       106       2 569      3 801      62 195,49         92 212,26        \n 20/02/2026  34        31        2 048      2 048      48 865,28         48 803,84        \n 23/02/2026  284       314       12 851     15 040     310 737,18        364 569,60       \n 24/02/2026  117       89        4 643      4 662      112 732,04        113 566,32       \n 25/02/2026  90        72        3 060      3 570      74 541,60         87 143,70        \n 26/02/2026  181       188       4 954      2 443      123 503,22        60 464,25        \n 27/02/2026  122       67        4 406      3 815      103 541,00        89 805,10        \n 02/2026     2 237     2 993     90 142     94 740     2 163 717,13      2 271 996,06     \n 02/03/2026  127       129       3 032      3 032      69 645,04         70 160,48        \n 03/03/2026  30        15        1 704      1 674      38 425,20         37 564,56        \n 04/03/2026  32        99        1 006      3 635      22 363,38         84 113,90        \n 05/03/2026  65        73        1 341      945        31 178,25         22 150,80        \n 06/03/2026  47        39        3 403      3 403      74 321,52         74 423,61        \n 09/03/2026  9         10        475        815        9 851,50          17 432,85        \n 10/03/2026  136       109       2 839      2 939      63 621,99         66 009,94        \n 11/03/2026  81        56        3 829      3 084      85 271,83         68 341,44        \n 12/03/2026  32        22        1 387      2 030      29 598,58         43 178,10        \n 13/03/2026  100       51        7 450      7 350      154 885,50        152 733,00       \n 16/03/2026  72        31        6 523      6 523      135 547,94        135 678,40       \n 17/03/2026  75        77        7 900      7 900      162 819,00        163 135,00       \n 18/03/2026  114       67        17 539     17 539     365 863,54        365 688,15       \n 19/03/2026  55        41        3 760      3 760      77 230,40         77 305,60        \n 20/03/2026  46        31        3 756      3 104      77 411,16         64 097,60        \n 23/03/2026  33        37        2 403      3 016      50 078,52         62 431,20        \n 24/03/2026  60        43        3 755      3 755      79 643,55         79 643,55        \n 25/03/2026  45        46        3 800      3 137      83 676,00         68 888,52        \n 26/03/2026  42        30        2 902      2 902      62 799,28         62 973,40        \n 27/03/2026  80        84        6 675      6 712      147 250,50        148 469,44       \n 30/03/2026  67        53        3 821      3 922      83 832,74         86 127,12        \n 31/03/2026  52        67        4 473      4 985      99 926,82         111 514,45       \n 03/2026     1 400     1 210     93 773     96 162     2 005 242,24      2 062 061,11     \n 01/04/2026  67        53        4 048      4 048      94 520,80         94 480,32        \n 02/04/2026  50        38        3 492      3 487      79 617,60         79 538,47        \n 07/04/2026  46        15        2 648      1 950      58 785,60         42 978,00        \n 08/04/2026  47        42        3 600      3 676      81 612,00         83 114,36        \n 09/04/2026  50        55        3 461      4 502      77 941,72         101 520,10       \n 10/04/2026  51        36        4 189      2 585      99 195,52         61 135,25        \n 13/04/2026  48        56        2 862      3 512      65 911,86         81 056,96        \n 14/04/2026  38        54        2 365      3 193      56 665,40         76 376,56        \n 15/04/2026  52        42        3 881      2 997      96 986,19         75 074,85        \n 16/04/2026  72        57        4 272      3 069      103 083,36        73 932,21        \n 17/04/2026  50        59        4 193      4 298      100 715,86        103 452,86       \n 20/04/2026  57        50        3 834      3 926      90 827,46         92 928,42        \n 21/04/2026  81        124       6 639      8 172      161 062,14        198 334,44       \n 22/04/2026  46        41        3 300      3 300      80 949,00         81 147,00        \n 23/04/2026  96        95        7 358      7 358      178 505,08        178 799,40       \n 24/04/2026  45        28        3 670      1 994      86 612,00         47 118,22        \n 27/04/2026  96        99        5 223      6 607      122 740,50        155 859,13       \n 28/04/2026  52        21        3 374      1 728      78 411,76         40 176,00        \n 29/04/2026  32        55        2 468      4 762      57 504,40         111 907,00       \n 30/04/2026  45        39        3 176      3 275      76 986,24         79 451,50        \n 04/2026     1 121     1 059     78 053     78 439     1 848 634,49      1 858 381,05     \n 04/05/2026  77        71        5 918      5 730      142 387,08        138 551,40       \n 05/05/2026  49        43        3 349      3 349      82 787,28         82 921,24        \n 06/05/2026  50        41        6 600      4 391      175 362,00        116 405,41       \n 07/05/2026  81        111       11 385     11 344     302 954,85        302 431,04       \n 08/05/2026  64        59        7 824      7 789      203 815,20        203 137,12       \n 11/05/2026  92        104       14 259     14 962     382 426,38        401 280,84       \n 12/05/2026  72        122       9 608      10 540     257 974,80        284 053,00       \n 13/05/2026  73        89        11 391     10 663     321 226,20        300 589,97       \n 14/05/2026  42        54        5 148      6 289      143 989,56        176 469,34       \n 15/05/2026  80        48        9 279      4 779      261 575,01        134 863,38       \n 18/05/2026  43        39        3 465      2 865      92 654,10         76 638,75        \n 19/05/2026  64        44        4 472      4 472      116 003,68        116 137,84       \n 20/05/2026  18        74        2 072      6 287      55 674,64         169 497,52       \n 21/05/2026  31        32        3 134      3 134      83 395,74         83 427,08        \n 22/05/2026  90        75        12 451     12 451     336 550,53        337 795,63       \n 25/05/2026  64        23        5 909      2 046      158 774,83        55 242,00        \n 26/05/2026  43        60        3 599      3 599      95 841,37         95 913,35        \n 27/05/2026  36        47        2 754      3 771      73 779,66         101 590,74       \n 28/05/2026  15        50        1 249      3 711      34 097,70         103 351,35       \n 29/05/2026  70        67        5 448      4 767      156 412,08        137 527,95       \n 05/2026     1 154     1 253     129 314    126 939    3 477 682,69      3 417 824,95     \n 01/06/2026  103       99        12 405     9 322      357 388,05        269 219,36       \n 02/06/2026  65        52        5 454      3 189      150 639,48        87 729,39        \n 03/06/2026  63        41        4 466      2 812      118 482,98        74 489,88        \n 04/06/2026  26        24        1 900      1 900      49 780,00         49 875,00        \n 05/06/2026  41        69        3 061      5 853      83 197,98         160 079,55       \n 08/06/2026  52        129       4 260      10 463     117 576,00        290 034,36       \n 09/06/2026  81        82        11 019     7 969      308 311,62        222 972,62       \n 10/06/2026  94        40        7 055      4 017      189 708,95        108 097,47       \n 11/06/2026  78        158       5 408      9 722      145 475,20        263 174,54       \n 12/06/2026  53        69        4 680      4 345      128 512,80        119 791,65       \n 15/06/2026  74        152       6 000      5 720      166 860,00        159 302,00       \n 16/06/2026  95        167       12 764     15 301     358 923,68        430 876,16       \n 17/06/2026  89        71        4 892      4 892      118 141,80        118 092,88       \n 18/06/2026  137       150       11 990     9 981      300 709,20        250 722,72       \n 19/06/2026  35        11        4 376      1 946      106 424,32        47 209,96        \n 22/06/2026  48        93        4 296      6 311      105 896,40        156 007,92       \n 23/06/2026  28        54        2 307      4 804      59 036,13         123 366,72       \n 24/06/2026  45        26        3 547      1 452      89 916,45         36 387,12        \n 25/06/2026  34        32        2 180      2 417      54 521,80         60 594,19        \n 26/06/2026  42        45        2 550      2 730      65 713,50         70 406,70        \n 29/06/2026  48        72        4 203      4 896      112 051,98        130 576,32       \n 30/06/2026  32        41        2 007      2 804      56 396,70         78 455,92        \n 06/2026     1 363     1 677     120 820    122 846    3 243 665,02      3 307 462,43     \n S1/2026     9 138     10 478    592 263    592 567    14 869 875,91     14 883 592,32    \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260706818402/en/\n(https://www.businesswire.com/news/home/20260706818402/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\nNicolas Mérigeau / Gaëlle Fromaigeat \n\nMedia Relations\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\nLouis-Victor Delouvrier / Alban Dufumier \n\nInvestor Relations France\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-07-06T16:40:00.183484111Z","server_sent_at_ms":1783356000183},"received_at":"2026-07-06T16:40:00.364Z","source_url":"https://www.businesswire.com/news/home/20260706818402/en/"},"analysis":{"id":"70258","press_release_id":"81145","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Medincell reported its half-year liquidity contract statement, revealing that the account held 676 shares and €1.17 million at June 30, 2026, compared to 980 shares and €1.16 million at the end of December 2025.\n\nDuring the first six months of 2026, the liquidity provider executed 9,138 buy-side transactions totaling 592,263 shares and 10,478 sell-side transactions totaling 592,567 shares, with traded volumes of roughly €14.87 million and €14.88 million respectively.\n\nManagement of the liquidity contract was transferred to Rothschild & Co Global Markets Solutions effective July 1, 2026, following a reorganization within the Rothschild & Co group, though the company stated the transfer has no impact on the contract's terms.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine regulatory filing regarding liquidity contract statistics."},"keyFigures":{"customDimensions":{"h1_buy_shares":592263,"h1_sell_shares":592567,"h1_buy_executions":9138,"h1_sell_executions":10478,"liquidity_shares_dec_31_2025":980,"liquidity_shares_jun_30_2026":676}},"quotedText":"","namedEntities":{"people":[{"name":"David Heuzé","role":"Head of Corporate and Financial Communications, and ESG"},{"name":"Grace Kim","role":"Chief Strategy Officer, U.S. Finance"},{"name":"Nicolas Mérigeau","role":"Media Relations"},{"name":"Gaëlle Fromaigeat","role":"Media Relations"},{"name":"Louis-Victor Delouvrier","role":"Investor Relations France"},{"name":"Alban Dufumier","role":"Investor Relations France"}],"products":["BEPO(®)","BEPO(®) Star","Risperidone LAI","UZEDY(®)","SteadyTeq™","Olanzapine LAI"],"companies":[{"name":"Medincell","ticker":"MEDCL"},{"name":"Rothschild Martin Maurel","relationship":"liquidity contract provider (former)"},{"name":"Rothschild & Co Global Markets Solutions (Europe) SA","relationship":"liquidity contract provider (new)"},{"name":"Teva Pharmaceuticals","relationship":"partner"}],"dollarAmounts":[{"amount":"1 173 521 €","context":"liquidity account balance at June 30, 2026"},{"amount":"14,869,875.91","context":"H1 2026 buy-side traded volume in EUR"},{"amount":"14,883,592.32","context":"H1 2026 sell-side traded volume in EUR"},{"amount":"1 159 804 €","context":"liquidity account balance at December 31, 2025"}]},"materialImpact":{"score":1,"reasoning":"This is a routine semi-annual regulatory disclosure regarding the company's liquidity contract. The trading statistics and administrative transfer of the contract provider do not constitute a material change to business operations or financial outlook."},"tickerRelevance":{"others":[],"primary":"MEDCL"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_regulatory_filing","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Medincell reported its half-year liquidity contract statement, revealing that the account held 676 shares and €1.17 million at June 30, 2026, compared to 980 shares and €1.16 million at the end of December 2025.\n\nDuring the first six months of 2026, the liquidity provider executed 9,138 buy-side transactions totaling 592,263 shares and 10,478 sell-side transactions totaling 592,567 shares, with traded volumes of roughly €14.87 million and €14.88 million respectively.\n\nManagement of the liquidity contract was transferred to Rothschild & Co Global Markets Solutions effective July 1, 2026, following a reorganization within the Rothschild & Co group, though the company stated the transfer has no impact on the contract's terms.","key_figures":{"customDimensions":{"h1_buy_shares":592263,"h1_sell_shares":592567,"h1_buy_executions":9138,"h1_sell_executions":10478,"liquidity_shares_dec_31_2025":980,"liquidity_shares_jun_30_2026":676}},"named_entities":{"people":[{"name":"David Heuzé","role":"Head of Corporate and Financial Communications, and ESG"},{"name":"Grace Kim","role":"Chief Strategy Officer, U.S. Finance"},{"name":"Nicolas Mérigeau","role":"Media Relations"},{"name":"Gaëlle Fromaigeat","role":"Media Relations"},{"name":"Louis-Victor Delouvrier","role":"Investor Relations France"},{"name":"Alban Dufumier","role":"Investor Relations France"}],"products":["BEPO(®)","BEPO(®) Star","Risperidone LAI","UZEDY(®)","SteadyTeq™","Olanzapine LAI"],"companies":[{"name":"Medincell","ticker":"MEDCL"},{"name":"Rothschild Martin Maurel","relationship":"liquidity contract provider (former)"},{"name":"Rothschild & Co Global Markets Solutions (Europe) SA","relationship":"liquidity contract provider (new)"},{"name":"Teva Pharmaceuticals","relationship":"partner"}],"dollarAmounts":[{"amount":"1 173 521 €","context":"liquidity account balance at June 30, 2026"},{"amount":"14,869,875.91","context":"H1 2026 buy-side traded volume in EUR"},{"amount":"14,883,592.32","context":"H1 2026 sell-side traded volume in EUR"},{"amount":"1 159 804 €","context":"liquidity account balance at December 31, 2025"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-06T16:41:46.626Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_regulatory_filing","sectorWeight":"biotech"}},"durationMs":106244,"modelName":"george-droid-qwen-72b"}}